SCHEMBL13614254

SCHEMBL13614254

CCC(C)N(C)Cc1cc(-c2ccc(CC(=O)O)c(F)c2)cc2c1OC(C)(C)CC2(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 3/20 0.39
CYP26B1 Q9NR63 3/20 0.39
GPR119 Q8TDV5 1/20 0.33
F2 P00734 2/20 0.33
F9 P00740 2/20 0.33
F10 P00742 2/20 0.33
CFD P00746 2/20 0.33
PLG P00747 2/20 0.33
PLAU P00749 2/20 0.33
PLAT P00750 2/20 0.33
F11 P03951 2/20 0.33
KLKB1 P03952 2/20 0.33
F7 P08709 2/20 0.33
AKR1B1 P15121 1/20 0.32
RXRA P19793 2/20 0.31
RXRB P28702 2/20 0.31
RXRG P48443 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
CTSK P43235 1/20 0.30
CTSC P53634 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13613837 0.88 CYP26A1 (0.49) CYP26A1CYP26B1F2F9F10
SCHEMBL13986015 0.84 CYP26A1 (0.40) CYP26A1CYP26B1GPR119F2F9
SCHEMBL13614255 0.82 PTGS2 (0.38) CYP26A1CYP26B1
SCHEMBL13614076 0.80 CYP26A1 (0.43) CYP26A1CYP26B1GPR119F2F9
SCHEMBL14223663 0.77 CYP26A1 (0.41) CYP26A1CYP26B1GPR119F2F9
SCHEMBL13613854 0.76 AKR1B1 (0.47) CYP26A1CYP26B1F2F9F10
SCHEMBL13986034 0.71 CYP26B1 (0.51) CYP26A1CYP26B1F2F9F10
SCHEMBL13613851 0.70 CYP26A1 (0.35) CYP26A1CYP26B1AKR1B1
SCHEMBL4511996 0.70 CYP26A1 (0.39) CYP26A1CYP26B1AKR1B1FFAR4
SCHEMBL14524821 0.68 PTGS2 (0.36) CYP26A1CYP26B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638648-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN INC. (US) 2009-12-29 US disclosed
US-7468391-B2 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2008-12-23 US disclosed
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 CYP26A1 15/4885CYP26B1 10/4885GPR119 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.